cytarabine has been researched along with Granulocytic Leukemia, Chronic, Stable Phase in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (34.88) | 18.2507 |
| 2000's | 24 (55.81) | 29.6817 |
| 2010's | 4 (9.30) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ammerlaan, RA; Chu, IW; Cornelissen, JJ; Deenik, W; Falkenburg, JH; Janssen, JJ; Kersten, MJ; Ossenkoppele, GJ; Schattenberg, A; Schipperus, M; Sinnige, HA; Smit, WM; Sonneveld, P; Thielen, N; Valk, PJ; van der Holt, B; van Marwijk Kooy, R; Verhoef, GE | 1 |
| Dengler, J; Fabarius, A; Falge, C; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Hochhaus, A; Hossfeld, DK; Kalmanti, L; Kanz, L; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Nerl, C; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Saussele, S; Schnittger, S; Schreiber, A; Spiekermann, K; Stegelmann, F; Waller, CF | 1 |
| Bloomfield, CD; Deangelo, DJ; Donohue, KA; Hars, V; Larson, RA; Linker, CA; Marcucci, G; Shea, T; Stock, W; Stone, RM | 1 |
| Allard, C; Berger, M; Berthou, C; Coiteux, V; Corm, S; Delmer, A; Eclache, V; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Jourdan, E; Legros, L; Mahon, FX; Maloisel, F; Nicolini, FE; Preudhomme, C; Rea, D; Rigal-Huguet, F; Roche-Lestienne, C; Rousselot, P; Vekhoff, A | 1 |
| Ayemou, R; Koffi, KG; Kouakou, B; Méité, N; Nanho, DC; Ndiaye, FS; Sanogo, I; Sawadogo, GD; Sékongo, YM; Tolo-Diebkilé, A | 1 |
| Berger, U; Engelich, G; Helmann, R | 1 |
| Abbrederis, K; Apfelbeck, U; Baldinger, C; Buder, R; Burgstaller, S; Duba, C; Eisterer, W; Fiegl, M; Fridrik, M; Gastl, G; Geissler, D; Greil, R; Hausmaninger, H; Hilbe, W; Köck, L; Krieger, O; Kühr, T; Lang, A; Lin, W; Linkesch, W; Lutz, D; Michlmayr, G; Pont, J; Seewann, H; Thaler, J; Zabernigg, A | 1 |
| Baccarani, M; Bolton, AE; Capdeville, R; Cervantes, F; Cornelissen, JJ; Druker, BJ; Fischer, T; Gathmann, I; Goldman, JM; Gratwohl, A; Guilhot, F; Hochhaus, A; Hughes, T; Kantarjian, H; Larson, RA; Lechner, K; Nielsen, JL; O'Brien, SG; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Simonsson, B; Taylor, K; Verhoef, G | 1 |
| Cella, D; Dobrez, DG; Druker, BJ; Glendenning, GA; Guilhot, F; Hahn, EA; Hensley, ML; Hudgens, SA; Larson, RA; O'Brien, SG; Sorensen, MV | 1 |
| Berthaud, P; Berthou, C; Buzyn, A; Cheron, N; Facon, T; Gardembas, M; Guilhot, F; Guilhot, J; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Vigier, M | 1 |
| Berger, U; Engelich, G; Hehlmann, R; Hochhaus, A; Reiter, A | 1 |
| Berger, U; Hehlmann, R | 1 |
| Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B | 1 |
| Clapisson, G; Hayette, S; Michallet, M; Nicolini, FE; Philip, I; Prebet, T; Tigaud, I | 1 |
| Cornelissen, JJ; Daenen, SM; Deenik, W; Löwenberg, B; Ossenkoppele, GJ; Schattenberg, AV; Schouten, HC; Smit, WM; van der Holt, B; Verdonck, LF; Verhoef, GE; Westveer, PH; Wittebol, S; Zachée, P | 1 |
| Barbany, G; Bengtsson, M; Göransson, H; Hagberg, A; Höglund, M; Isaksson, A; Olsson-Strömberg, U; Simonsson, B; Wickenberg-Bolin, U | 1 |
| Fyles, G; Hasegawa, W; Kiss, T; Lipton, JH; Loach, D; Lockwood, G; Messner, H; Minden, M; Rifkind, J; Tejpar, I; Tsang, R; Zaretsky, Y | 1 |
| Anstrom, KJ; Li, Y; Reed, SD; Schulman, KA | 1 |
| Carella, AM; Frassoni, F; Parodi, C; Podesta, M; Pollicardo, N; Pungolino, E; Rabitti, C; Raffo, MR; Sessarego, M; Vimercati, R | 1 |
| Guilhot, F | 1 |
| Abgrall, JF; Bauters, F; Brice, P; Cassasus, P; Dine, G; Guilhot, F; Harousseau, JL; Ifrah, N; Rochant, H; Tilly, H | 1 |
| Hilbe, W; Thaler, J | 1 |
| Abgrall, JF; Bauters, F; Blanc, M; Bordessoule, D; Bouabdallah, R; Brière, J; Chastang, C; Colombat, P; Desablens, B; Fiere, D; Guerci, A; Guilhot, F; Guyotat, D; Harousseau, JL; Ifrah, N; Maloisel, F; Morice, P; Najman, A; Navarro, M; Nicolini, F; Rochant, H; Tanzer, J; Tertian, G; Vilque, JP | 1 |
| Aulitzky, WE; Busemann, C; Huber, C; Huhn, D; Kolbe, K; Neubauer, A; Peschel, C; Schleiermacher, E; Schneller, F; Siegert, W | 1 |
| Chalmers, EA; Clark, RE; Crotty, G; Fielding, A; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, SM; McCann, SR; Newland, AC; Sharp, RA; Sproul, AM; Tansey, P; Watson, W | 1 |
| Beran, M; Estey, E; Kantarjian, HM; Keating, MJ; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Sacchi, S; Talpaz, M | 1 |
| Chalmers, EA; Clark, RE; Crotty, G; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, SM; McBride, N; McCann, SR; Newland, AC; Sharp, RA; Singer, IO; Sproul, AM; Tansey, PJ; Watson, W | 1 |
| Chott, A; Fiegl, M; Gisslinger, H; Lechner, K; Seewann, HL | 1 |
| Andreeff, M; Beran, M; Cortes, J; Giles, FJ; Giralt, S; Kantarjian, HM; Keating, MJ; Koller, C; Kornblau, S; O'Brien, S; Rios, MB; Smith, TL; Talpaz, M | 1 |
| Advani, SH; Aydogdu, I; Aziz, Z; Caviles, AP; Chaoj, TY; Chasen, MR; Chen, S; Fahed, Z; Giles, FJ; Lynott, AM; Shan, J; Supandiman, I; Tee, GY | 1 |
| Ezaki, K | 1 |
| Bandini, G; Isidori, A; Malagola, M; Martinelli, G; Piccaluga, P; Ricci, P; Rosti, G; Stanzani, M; Testoni, N; Tosi, P; Tura, S; Visani, G | 1 |
| Fricová, M; Guman, T; Hlebasková, M; Kafková, A; Raffac, S; Stecová, N; Tóthová, E | 1 |
| Cheson, B; Cortes, J; Gajewski, J; Giles, FJ; Kantarjian, HM; Mallard, S; Murgo, A; O'Brien, S; Rios, MB; Smith, TL; Talpaz, M | 1 |
| Cavenagh, JD; Kelsey, SM; Lillington, DM; McBride, NC; Murrell, C; Newland, AC | 1 |
| Consoli, U; Giustolisi, GM; Giustolisi, R; Guglielmo, P; Inghilterra, G; Palumbo, GA; Stagno, F | 1 |
| Aoki, N; Beck, JR; Giles, FJ; Guilhot, F; Guilhot, J; Wirt, DP | 1 |
| Beran, M; Cortes, J; Giles, FJ; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Rios, MB; Talpaz, M | 1 |
| Banyai, A; Barta, A; Foldi, J; Gidali, J; Gopcsa, L; Kalasz, L; Pajor, L; Paloczi, K; Regeczy, N | 1 |
| Karle, H; Nielsen, H; Nielsen, JL | 1 |
| Chan, TK; Chiu, E; Liang, R; Todd, D | 1 |
| Beran, M; Estey, EH; Feldman, E; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Pierce, S; Talpaz, M | 1 |
| Ahmed, T; Arlin, Z; Biguzzi, S; Feldman, E; Mittelman, A; Puccio, C | 1 |
2 review(s) available for cytarabine and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Survival Analysis | 2008 |
Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Randomized Controlled Trials as Topic; Survival Analysis | 2000 |
24 trial(s) available for cytarabine and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pain; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sample Size; Treatment Outcome; Young Adult | 2013 |
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Staging; Palliative Care; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Polyethylene Glycols; Proto-Oncogene Proteins c-abl; Pyrimidines; Recombinant Proteins; Remission Induction; RNA, Neoplasm; Stem Cells; Survival Analysis; Thrombocytopenia; Transcription, Genetic; Treatment Outcome | 2010 |
[Imatinib combination therapies--the new CML Study 4].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Survival Rate; Treatment Outcome | 2002 |
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Life Tables; Male; Middle Aged; Nervous System Diseases; Recombinant Proteins; Treatment Outcome | 2003 |
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Survival Rate | 2003 |
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cross-Over Studies; Cytarabine; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Logistic Models; Male; Middle Aged; Multivariate Analysis; Piperazines; Prospective Studies; Pyrimidines; Quality of Life | 2003 |
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Safety; Thrombocytopenia | 2003 |
Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Prospective Studies; Pyrimidines; Survival Rate | 2004 |
[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome | 2004 |
High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.
Topics: Adolescent; Adult; Aged; Cytarabine; Cytogenetics; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous | 2007 |
Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Female; Humans; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Multicenter Studies as Topic; Pilot Projects; Randomized Controlled Trials as Topic | 1993 |
A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Cytarabine; Female; France; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Recombinant Proteins; Remission Induction; Treatment Outcome | 1993 |
Comparative analysis of two consecutive phase II studies with IFN-alpha and IFN-alpha + ara-C in untreated chronic-phase CML patients. Austrian CML Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Austria; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Recombinant Proteins; Retrospective Studies | 1996 |
The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cytarabine; Drug Tolerance; France; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Randomized Controlled Trials as Topic; Recombinant Proteins | 1996 |
Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Interleukin-3; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Philadelphia Chromosome | 1996 |
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Hydroxyurea; Interferon Type I; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prognosis; Recombinant Proteins; Time Factors | 1997 |
Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 1998 |
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Genetic Markers; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Prognosis; Risk Factors; Survival Rate | 1999 |
A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Survival Rate; Treatment Outcome | 2000 |
Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Remission Induction | 2000 |
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Harringtonines; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prognosis; Survival Analysis | 2000 |
Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Prospective Studies; Survival Rate; Treatment Outcome | 2000 |
Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prednisolone; Prednisone; Risk Factors; Survival Rate; Therapeutic Equivalency; Treatment Outcome; Vincristine | 2001 |
17 other study(ies) available for cytarabine and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; RNA, Messenger; RNA, Neoplasm; Splenomegaly; Treatment Outcome; Young Adult | 2014 |
[Therapeutic impact of alpha interferon in chronic myelogenous leukaemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Remission Induction; Retrospective Studies; Socioeconomic Factors; Virus Activation; Young Adult | 2010 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine | 2005 |
Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Imatinib Mesylate; Interferons; Lenograstim; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Transplantation, Autologous | 2005 |
Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2007 |
Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2007 |
Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Blood Transfusion, Autologous; Cell Separation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; RNA, Messenger; RNA, Neoplasm; Time Factors; Treatment Outcome | 1993 |
Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells.
Topics: Adult; Cytarabine; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous | 1997 |
Persisting bone marrow aplasia following interferon-alpha combined with ara-C for chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Dose-Response Relationship, Drug; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Pancytopenia | 1999 |
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2000 |
In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Differentiation; Cell Separation; Cytarabine; DNA Fragmentation; Electrophoresis, Agar Gel; Female; Granulocytes; Humans; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Macrophage-1 Antigen; Male; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Tretinoin; Tumor Cells, Cultured | 2000 |
Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Decision Trees; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Markov Chains; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2001 |
Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Purging; Caspase 14; Caspases; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Recombinant Proteins; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2001 |
Initial cytoreduction by mitoxantrone and cytarabine has no impact on the outcome of interferon-alfa-2b therapy in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Longitudinal Studies; Middle Aged; Mitoxantrone; Philadelphia Chromosome; Pilot Projects; Recombinant Proteins; Remission Induction | 1992 |
Non-aggressive therapy for chronic myeloid leukaemia in blastic transformation.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Hydroxyurea; Leukemia; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Remission Induction; Thioguanine; Vincristine | 1992 |
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Research Design; Survival Analysis; Treatment Outcome | 1992 |
Intensive chemotherapy with interferon for induction of true remission in chronic phase of chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Interferon Type I; Leukemia, Myeloid, Chronic-Phase; Male; Remission Induction | 1990 |